Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) includes a group of clinically, genetically, and pathologically heterogeneous neurodegenerative disorders, affecting the fronto-insular-temporal regions of the brain. Clinically, FTD is characterized by progressive deficits in behavior, executive function, and language and its diagnosis relies mainly on the clinical expertise of the physician/consensus group and the use of neuropsychological tests and/or structural/functional neuroimaging, depending on local availability. The modest correlation between clinical findings and FTD neuropathology makes the diagnosis difficult using clinical criteria and often leads to underdiagnosis or misdiagnosis, primarily due to lack of recognition or awareness of FTD as a disease and symptom overlap with psychiatric disorders. Despite advances in understanding the underlying neuropathology of FTD, accurate and sensitive diagnosis for this disease is still lacking. One of the major challenges is to improve diagnosis in FTD patients as early as possible. In this context, biomarkers have emerged as useful methods to provide and/or complement clinical diagnosis for this complex syndrome, although more evidence is needed to incorporate most of them into clinical practice. However, most biomarker studies have been performed using North American or European populations, with little representation of the Latin American and the Caribbean (LAC) region. In the LAC region, there are additional challenges, particularly the lack of awareness and knowledge about FTD, even in specialists. Also, LAC genetic heritage and cultures are complex, and both likely influence clinical presentations and may modify baseline biomarker levels. Even more, due to diagnostic delay, the clinical presentation might be further complicated by both neurological and psychiatric comorbidity, such as vascular brain damage, substance abuse, mood disorders, among others. This systematic review provides a brief update and an overview of the current knowledge on genetic, neuroimaging, and fluid biomarkers for FTD in LAC countries. Our review highlights the need for extensive research on biomarkers in FTD in LAC to contribute to a more comprehensive understanding of the disease and its associated biomarkers. Dementia research is certainly reduced in the LAC region, highlighting an urgent need for harmonized, innovative, and cross-regional studies with a global perspective across multiple areas of dementia knowledge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resources for mental health: scarcity, inequity, and inefficiency
Saxena, S., Thornicroft, G., Knapp, M., & Whiteford, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61239-2 · Cited by 1,789 · cited 1×
“Barriers to diagnosis in the region include inadequate training (7, 8), especially among primary care physicians (2, 9), together with insufficient access to both healthcare and specialized services such as neuropsychological assessment (2, 6).”
BackgroundNeuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 1×
“Biomarkers include some of the pro- and antiinflammatory cytokines, chemokines, and secondary messengers that coordinate the immune response through regulation of innate and adaptive responses in the periphery (188, 189).”
BackgroundPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 1×
“92 with a specificity of 81% and sensitivity of 93% to differentiate between these variants of FTD and AD (173).”
BackgroundInnate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437 · cited 1×
“It has been suggested that immune activation may be an early cause of neurodegeneration (180) or that the addition or accumulation of tau or TDP-43 induces an increased cytotoxic response leading to chronic neuroinflammation (181–183).”
BackgroundLong pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210 · cited 1×
“In Europe and North America, the C9orf72 expansion accounted for nearly 40% of familial and 8% of sporadic ALS, as well as 25% of familial and 6% of sporadic FTD cases (64).”
BackgroundHol, E. M., & Pekny, M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.004 · Cited by 917
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 1×
“One study also found that CSF sTREM2 levels decreased in a larger cohort of patients with FTD, including carriers with C9orf72 and GRN mutations (204).”
BackgroundInflammatory Response in the CNS: Friend or Foe?
Sochocka, M., Diniz, B. S., & Leszek, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0297-1 · Cited by 573
Cited by
A predictive coding framework of allostatic–interoceptive overload in frontotemporal dementia
Migeot, J. A., Duran-Aniotz, C. A., Signorelli, C. M., Piguet, O., & Ibáñez, A. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.08.005 · Cited by 76
Self-citationA synergetic turn in cognitive neuroscience of brain diseases
Ibanez, A., Kringelbach, M. L., & Deco, G. (2024) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2023.12.006 · Cited by 65
Intrinsic timescales and predictive allostatic interoception in brain health and disease
Ibanez, A., & Northoff, G. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105510 · Cited by 36
Allostatic interoception and brain health: From neurodegeneration to social adversities
Migeot, J., & Ibáñez, A. (2025) · Encyclopedia of the Human Brain · doi:10.1016/b978-0-12-820480-1.00025-5 · Cited by 10
Self-citation
Metadata
- Authors
- Duran-Aniotz, C., Orellana, P., Leon Rodriguez, T., Henriquez, F., Cabello, V., Aguirre-Pinto, M. F., Escobedo, T., Takada, L. T., Pina-Escudero, S. D., Lopez, O., Yokoyama, J. S., Ibanez, A., Parra, M. A., & Slachevsky, A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2021-06-24
- Volume
- 12
- Pages
- 663407-663407
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W3168390889
- Cited by
- 26
- References
- 63
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries. https://app.cochat.ai/papers/10.3389/fneur.2021.663407
- The paper
- Duran-Aniotz, C., Orellana, P., Leon Rodriguez, T., Henriquez, F., Cabello, V., Aguirre-Pinto, M. F., Escobedo, T., Takada, L. T., Pina-Escudero, S. D., Lopez, O., Yokoyama, J. S., Ibanez, A., Parra, M. A., & Slachevsky, A. (2021). Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries. Frontiers in Neurology. https://doi.org/10.3389/fneur.2021.663407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.